Latest Certolizumab pegol Stories
Improved outcomes for fistula closures observed in PRECiSE 2 trial under maintenance therapy with stable dosing of CIMZIA(R) every four weeks HOLLYWOOD, Fla., Dec.
UCB announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
SAN FRANCISCO, Oct.
BURLINGTON, ONTARIO--(Marketwire - Oct.
UCB, a Belgium-based biopharmaceutical and specialty chemical company, has presented positive data from a large, prospective study investigating endoscopic improvement in Crohn's disease with a biologic compound.
ORLANDO, Fla. Oct.
ORLANDO, Fla., Oct. 6 /PRNewswire/ -- UCB today presented data from a large, prospective study investigating endoscopic improvement in Crohn's disease (CD) with a biologic compound.
UCB's certolizumab is marketed under the brand name Cimzia. The submission for rheumatoid arthritis treatment, if accepted, will make it the first and only PEGylated, Fc-Free anti-TNF (tumor necrosis factor) alpha biologic therapy in Europe.
The European marketing authorisation application for Cimzia(R) has been filed. Subject to approval, Cimzia(R) will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.
LONDON (Reuters) - UCB's experimental drug Cimzia is effective and well-tolerated in treating Crohn's disease, a chronic inflammatory disorder of the digestive tract, researchers said on Tuesday.
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.